ArticleHemaSphere2022
EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer.
Article in HemaSphere, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 3 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- Personalized Antithrombotic Therapy After Percutaneous Coronary Intervention: A Systematic Review of Risk-Stratified Approaches.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Pooled it
- Chinese expert consensus on clinical management of hepatopathy-related thrombocytopenia (2023 edition).Hepatology international · 2025Guideline
- [Concise guidelines for the clinical management of thrombocytopenia in cirrhosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Guideline
- Thrombocytopenia as a Bleeding Risk Factor in Atrial Fibrillation and Coronary Artery Disease: Insights From the AFIRE Study.Journal of the American Heart Association · 2023Trial
- Platelet-derived mitochondrial transfer in cancer metastasis: mechanisms, functional consequences, and translational opportunities.Clinical & experimental metastasis · 2026Review
- Quantitative longitudinal photoacoustic imaging of vascular oxygenation for therapy response monitoring in Non-Hodgkin lymphoma.Photoacoustics · 2026Article
- Transcatheter Aortic Valve Implantation in Cancer Patients: A Contemporary Review of the Specific Challenges, the Outcomes, Risk Stratification, and Decision-Making.Medicina (Kaunas, Lithuania) · 2026Review
- Antithrombotic Therapy in Primary and Secondary Prevention of Coronary Artery Disease.Journal of clinical medicine · 2026Review
- Position Statement on the Management of Antithrombotic and Anticoagulant Therapy in Dengue - 2026.Arquivos brasileiros de cardiologia · 2026Article
- Anticoagulants beyond coagulation: a narrative review of cardiovascular effects.Cardiovascular research · 2026Review
- Navigating the Hemostatic Balance: Anticoagulation and Antiplatelet Therapy in Patients with Thrombocytopenia.Journal of clinical medicine · 2026Review
- Non-ST-Segment Elevation Myocardial Infarction as the Initial Presentation of Chronic Lymphocytic Leukemia.JACC. Case reports · 2026Article
- Toward platelet-count-adaptive anticoagulation in cancer thrombocytopenia: a standards-first, equity-aware proposal.Journal of thrombosis and thrombolysis · 2026Article
- Review
- Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL.Blood advances · 2026Article
- Understanding Cardio-Oncology: A Survey-Based Study Conducted by the Heart Failure Association of the Polish Cardiac Society and the Polish Society of Clinical Oncology.Journal of clinical medicine · 2026Article
- TGFβ enhances platelet-breast-cancer-cell interaction and promotes platelet aggregation.The FEBS journal · 2026Article
- Anticoagulation Quality Improvement Project: Reducing Noncompliant Anticoagulation Administrations in Patients With Cancer and Thrombocytopenia.Clinical journal of oncology nursing · 2026Article
- Venous Thromboembolism Management and Anticoagulation Opportunities in Cancer Patients.European cardiology · 2026Review
- Atrial fibrillation post hematopoietic stem cell transplant: incidence, risk factors, and management challenges.Frontiers in cardiovascular medicine · 2026Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 11 institutions in 10 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In cancer patients, thrombocytopenia can result from bone marrow infiltration or from anticancer medications and represents an important limitation for the use of antithrombotic treatments, including anticoagulant, antiplatelet, and fibrinolytic agents. These drugs are often required for prevention or treatment of cancer-associated thrombosis or for cardioembolic prevention in atrial fibrillation in an increasingly older cancer population. Data indicate that cancer remains an independent risk factor for thrombosis even in case of thrombocytopenia, since mild-to-moderate thrombocytopenia does not protect against arterial or venous thrombosis. In addition, cancer patients are at increased risk of antithrombotic drug-associated bleeding, further complicated by thrombocytopenia and acquired hemostatic defects. Furthermore, some anticancer treatments are associated with increased thrombotic risk and may generate interactions affecting the effectiveness or safety of antithrombotic drugs. In this complex scenario, the European Hematology Association in collaboration with the European Society of Cardiology has produced this scientific document to provide a clinical practice guideline to help clinicians in the management of patients with cancer and thrombocytopenia. The Guidelines focus on adult patients with active cancer and a clear indication for anticoagulation, single or dual antiplatelet therapy, their combination, or reperfusion therapy, who have concurrent thrombocytopenia because of either malignancy or anticancer medications. The level of evidence and the strength of the recommendations were discussed according to a Delphi procedure and graded according to the Oxford Centre for Evidence-Based Medicine.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.